key: cord-0748098-au87jjke
authors: Mendie, Love Edet; Hemalatha, S.
title: Molecular Docking of Phytochemicals Targeting GFRs as Therapeutic Sites for Cancer: an In Silico Study
date: 2022-01-06
journal: Appl Biochem Biotechnol
DOI: 10.1007/s12010-021-03791-7
sha: 5281d5c15554392f36567a74162bebbdf83d954b
doc_id: 748098
cord_uid: au87jjke

Drug delivery in a safe manner is a major challenge in the drug development process. Growth factor receptors (GFRs) are known to have profound roles in the growth and progression of cancerous cells making these receptors a therapeutic target in the effective treatment of cancer. This work focused on exploring bioactive compounds that can target GFRs using in silico method. In this study, 50 bioactive compounds from different plant sources were screened as anticancer agent against GFRs using drug likeness parameters of Lipinski’s rule of five. The molecular docking was performed between phytochemicals and GFRs. Ligands with acceptable drug likeness and binding energy comparable to the standard drugs were further screened to determine their pharmacokinetic activities. This study showed phytochemicals with the binding energy comparable with the standard drugs (Dovitinib and Gefitinib), while ADME, bioactivity score, and bioavailability radar analysis gave further insight on these compounds as potent anticancer agents.

Multiple alterations in the gene expression lead to imbalance in cellular proliferation resulting in abnormal growth of cells called cancer. Over the years, cancer has been a persistent public health problem recorded as the major cause of death in both developed and developing countries worldwide [1, 2] . Research shows that an estimated number of 23.6 million new cases of cancer are likely to be recorded per year by 2030 [3] . Cancerous cells have special ability of survival, immortality, self-sufficiency of growth signals, unlimited replication, gene instability, evading programmed cell death, continuous angiogenesis, and diverse mutations [4] . Growth factor receptors (GFRs) are proteins that have profound roles in tumor growth of cell, metastasis, angiogenesis, cell survival, cell death, cell migration, differentiation, organogenesis, neovascularization, and chemoresistance, activated by binding with their ligands (growth factors) [5] [6] [7] . These receptors highly involved in cancer progression include epidermal growth factor receptors (EGFRs), insulin-like growth factor receptor (IGFR), vascular endothelial growth factor receptor (VEGFR), transforming growth factor-beta receptor (TGF-βR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR). In some cancer, these receptors are often overexpressed leading to uncontrolled proliferation and differentiation [8] , and their amplification activates both inherent and acquired resistance to cancer treatments. Overexpression of HER-2 gene was found in breast, bladder, lung, and glial carcinomas; HER-3 gene in aggressive metastatic breast, ovarian, lung, gastric, invasive urothelial bladder, and endometrial carcinomas; VEGFR1-3genes found in large number of tumors like bladder, colon, breast, lung, brain, prostate, gastric, kidney, thyroid, and ovarian cancer cells; FGFR-2 gene in gastric, breast, endometrial, and lung carcinomas [6, 9] . The role of these receptors in cancer progression has made them a necessary therapeutic target for effective cancer therapy.

Presently, the treatment of cancer involves the use of chemotherapy, radiotherapy, immunotherapy, surgery, and anticancer drugs, all of which have been proven to be less effective due to disadvantages of recurrence, drug resistance, effect on non-targeted cell, and other various side effects and toxicity that accompanies them [2, 4] .

Studies have shown that phytochemicals are powerful anticancer agents, with benefits greater than synthetic compounds, ranging from less toxicity, ease of extraction, to large abundance [10] . About 35% of cancer cases can be addressed by establishing a proper dieting which largely involves the consumption of plant-derived foods such as vegetables, fruits, and whole grains that contains carotenoids, flavonoids, and phenolics [11] [12] [13] . Phytochemicals possess various mechanisms to shut down or slow down cancer growth and progression by reducing oxidative stress, suppressing proliferation of cells, causing programmed cell death, preventing angiogenic process, and cell cycle arrest [2, 11] . Studies showed that not less than 60 phytochemicals are currently in the pipeline as potential anticancer agents [14] [15] [16] . Developing anticancer drug requires blocking one or more proteins or pathways involved in cancer development. In this present study, 50 phytochemicals were evaluated against EGFRs (HER-2 and HER-3), VEGFR (VEGFR-2 and VEGFR-3), and FGFR (FGFR-2) to determine potential lead agents for the development of anticancer drugs.

Fifty bioactive compounds from different plant sources collated from public database and published research papers were downloaded from https:// pubch em. ncbi. nlm. nih. gov in SDF format (Fig. 1) . Also, two standard drugs Dovitinib and Gefitinibwith Pubmed IDCID_135398510 and CID_123631 respectively were downloaded in 3D Sdf format for comparism with the phytochemicals. Using the software open babel (http:// openb abel. org/ wiki/ Main_ Page), these ligands were changed to PDB format which makes them suitable for docking analysis. This was followed by setting the torsion requirements for proper binding using Autodock 4.2.6 parameters.

3D structures of human endothelial receptor (HER-1 and HER-2), vascular endothelial growth factor receptor (VEGFR-2 and VEGFR-3), and fibroblast growth receptor (FGFR-2) were downloaded from RCSB protein data bank (http:// www. rcsb. org/ pdb/ home/ home. do) with PDB ID 3PP0 for HER-2, 6OP9 for HER-3, 3VHE for VEGFR-2, 4BSJ for VEGFR-3, and 2PVF for FGFR-2. Using Autodock 4.2.6, removal of water molecules and addition of polar hydrogen and Kollman's charges were done, and these proteins were saved in PDBQT format.

After the proteins and ligands preparation, molecular docking was executed using Autodock 4.2.6. For binding to take place, x, y, and z dimensions were set at 60 × 60 × 60 with a resolution of 0.500 Å and grid box centered to obtain favorable docking conformations. The grid file was saved as (.gpf) file and run autogrid. Docking calculation was then carried out using the Lamarckian genetic algorithm with the default at 10 runs. Dock file was saved as dpf and after running autodock, final docked results were obtained in (.dlg) file which showed 

Lipinski's RO5 is used for evaluation of drug likeness of a compound, a necessary step in drug discovery which helps to determine if a certain compound is likely to be orally active. In this study, ligands were screened for the RO5 using the Supercomputing facility for bioinformatics and computational biology (http:// www. scfbio-iitd. res. in/ softw are/ drugd esign/ lipin ski. jsp) [17, 18] . Bioactive compounds with binding energy comparable to standard drugs were subjected to this analysis.

Pharmokinetics parameters such as Absorption, Distribution, Metabolism, and Excretion were evaluated in the ligands using SwissADME (http:// www. swiss adme. ch/ index. php). The essence of this assay is to provide insights that will be useful in drug research and development process.

The bioactivity score of ligands was determined employing online Molinspiration software (http:// www. molin spira tion. com/). This was done by applying canonical SMILES of ligands obtained from PubChem. Properties analyzed include G-protein coupled receptors (GPCR), enzyme inhibitors (EI), kinase inhibitors (KI), nuclear receptors ligands (NRL), and ion channel modulators (ICM). The bioavailability radar ligands were determined by using Swiss ADME (http:// www. swiss adme. ch/ index. php) which instantly shows if a compound is orally bioavailable. 

Due to the roles growth factor receptors play in the development and progression of cancer, it is necessary to develop suitable drug candidates that can effectively inhibit growth factors at the sites of receptors with little or no effects. Binding affinity between ligands and receptors is determined by the binding energy, the lower the energy, the higher the binding affinity [9] . For this purpose, 50 bioactive compounds ( Fig. 1) were screened against ERRB2/ HER-2, ERRB3/HER-3, VEGFR-2, VEGFR-3, and FGFR-2. Commonly used anticancer drugs (Dovitinib and Gefitinib) that have activities against the target receptors were docked against the proteins and their binding energies used as comparison with the binding energies of the selected. After docking, the binding energy(kcal/mol), number of hydrogen bond, inhibitory constant (μM/nM), and amino acids involved in hydrogen bonding were noted. Out of the 50 phytochemicals, 14 have binding energy comparable to the standard drug for HER-2 (Table 1 and Fig. 2 ). Dovitinib and Gefitinib have binding energies Nineteen phytochemicals for HER-3 as shown in Table 2 and Fig. 3 have Dovitinib and Gefitinib with binding energies of − 8.77 kcal/mol and − 6.89 kcal/mol, with amino acid involved in hydrogen bond as LEU771 for Dovitinib and CYS721 and LEU771 for Gefitinib.

Six phytochemicals for VEGFR-2 as shown in Table 3 and Fig. 4 have − 8.84 kcal/mol and − 8.70 kcal/mol binding energies for Dovitinib and Gefitinib respectively and amino acids GLU917 for Dovitinib and ASP1046 and CYS919 for Gefitinib.

Ten phytochemicals for VEGFR-3 as seen in Table 4 and Fig. 5 have binding energies of − 6.07 kcal/mol and − 5.94 kcal/mol for Dovitinib and Gefitinib, respectively, having amino acid SER455, GLN457, and LEU454 for Dovitinib and ASN515, TYR448, and GLU391 for Gefitinib.

Lastly, 19 phytochemicals have binding energy comparable to standard drug for FGFR-2 (Table 5 and Fig. 6 ); Dovitinib has an energy of − 6.72 kcal/mol with amino acid involved in hydrogen bond as ASN571, while Gefitinib has a binding energy of − 7.84 kcal/mol and amino acid ALA567. From these results, we selected 13 phytochemicals with the lowest binding energy comparable to standard drugs found in at least three of the target proteins; these were used for further in silico studies. 

Drug properties of the 13 selected phytochemicals were screened by Lipinski rule of five and ADME, which was followed by determining the bioavailability radar and bioactive score of the ligands. Lipinski's rule of five checked parameters like molecular weight, hydrogen donor, hydrogen acceptor, lipophilicity, and molar refractivity [17, 18] . Andrograholide, Bassic acid, Curdione, Nectandrin B, Nimbolide, salvicine, Withaferin A, and Hecogenin satisfied all the five criteria of Lipinski; Tetrandine did not pass the criteria while the others have deviation in at most one of the criteria which is still acceptable ( Table 6 ).

The phytochemicals were screened for ADME properties calculated from SwissADME, a free web tool which predicts and evaluates pharmacokinetics and drug likeness of molecules and built on several models [19] . In silico pharmacokinetics of the ligands as shown in Table 7 reveals that the drug likeness and pharmacokinetics of some of the phytochemicals are comparable to the standard drugs. The estimated solubility (ESOL) showed the phytochemicals curdione, andrographolide, and salvicine to be more soluble than the standard drugs Dovitinib and Gefitinib with lipophilicity comparable to Dovitinib but less than Gefitinib. Lipophilicity expressed as iLogP affects the absorption of drug, the lower the iLOGP value, the higher the absorption, and vice versa. Gastrointestinal absorption (GIA) and blood-brain barrier (BBB) permeation are predicted by BOILED model which utilizes the polarity and lipophilicity of compounds [20] . GIA was high for all the ligands except oleanolic acid and ursolic acid. In line with this, the bioavailability score of all the ligands falls in the normal range except that of ursolic and oleanolic acids. Major therapeutic agents are substrates to p-glycoprotein, which in most cases have the potential to reduce absorption, permeability, oral bioavailability, and retention time of drugs [21, 22] . P-glycoproteins are overly expressed in cancer cells, a major barrier in cancer treatment that causes drug efflux and makes chemotherapy quite ineffective [22, 23] . Hence, ligands that are non-substrate of p-gp are most preferable for cancer treatment.

As shown in Table 7 , most of the phytochemicals are non-inhibitors of CYP3A4 and CYP1A2, members of drug-metabolizing enzymes cytochrome P450, an enzyme that possesses important role in drug metabolism. The interaction of cytochrome 450 isoenzymes with drug could result in either rapid metabolism when the drug is a substrate of any CYP causing induction or accumulation of the drug when the drug is an inhibitor that causes inhibition, which in both cases are undesirable [24] . Therefore in silico analysis in predicting the interaction of compounds or drugs with CYP isoenzymes is important in drug development process.

Bioavailability radar provides a rapid assessment of the drug likeness of a compound. As seen in Fig. 6 , the pink area shows the optimal range of each parameter; when considering the parameters of a phytocompound, the radar plot of the compound has to fall in the pink area in order to be considered drug-like; hence, the ligands are either predicted to be orally bioavailable or not orally bioavailable via the radar plot. Flexibility (FLEX) and polarity (polar) are two essential properties that determine the bioavailability of compounds. Flexibility is determined by rotatable bonds; compounds with rotatable bonds > 10 are predicted to have low oral bioavailability while polarity as determined by topological polar surface implies that compound with TPSA > 20 Å 2 < 130 Å 2 have high oral bioavailability [24] . Seven of the phytochemicals (Andrographolide, Curdione, Nectandrin B, Nimbolide, Salvicine, Withaferin A, and Hecogenic) under study are noted to satisfy the radar plot criteria and hence can be suggested to be orally bioavailable (Fig. 7) .

Bioactivity score is used to calculate the drugability properties of ligands such as GPCR, ICM, KI, NRL, PI, and EI. Molinspiration online server was used to predict the scores of the ligands. Scores greater than 0.00 denote high activity, scores ranging from − 0.5 to − 0.00 show moderate activity, and scores lower than − 0.5 imply inactivity [25] . The phytochemicals under study showed a good score of high to moderate activity except for Hecogenic that showed inactivity in KI with a score of − 0.57 as shown in Table 8 . For GPCR and NRL, Andrographolide showed the highest score of 0.32 and 0.94, respectively; salivicine showed the highest score of 0.50 for ICM; Withaferin A had the highest score of 0.94 for EI; and Andrographolide and Salivicine both showed a high score of 0.26 for PI. Comparing this to the standard drugs, Dovitinib has good scores for all the properties while Gefitinib showed inactivity in some of the properties as seen in Table 8 . Good bioactivity scores revealed the potentials of these bioactives as potent therapeutic agents, the higher the scores, the better the activity.

In silico study is carried out to explore the potentials of various phytochemicals to inhibit cancer growth and progression through modulation of growth factor receptors. Based on our analysis, seven phytochemicals (Andrographolide, Curdione, Nectandrin B, Nimbolide, Salvicine, Withaferin A, and Hecogenic) possessed drug likeness and pharmacokinetics activities that are comparable with the standard drugs (Dovitinib and Gefitinib). This reveals that bioactive compounds have the ability to bind with GFRs causing inhibition of growth factors which in turn hinders cancer cell proliferation. Further investigation is needed to establish the pharmacodynamics and kinetic properties of these phytochemicals; also, mechanism of action of these phytochemicals as nanoparticle carrier of anticancer drug for effective cancer treatment can be found.

The global burden of cancer: Priorities for prevention

Phytochemicals in cancer treatment: From preclinical studies to clinical practice

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Screening the efficacy of compounds from ghee to control cancer: An in silico approach

Molecular docking and interactions between vascular endothelial growth factor (VEGF) receptors and phytochemicals: An insilico study

Growth factor receptors: promising drug targets in cancer

The fibroblast growth factor signaling pathway. Wiley interdisciplinary reviews

Tyrosine kinase receptors as attractive targets of cancer therapy

Analysis of plant-derived phytochemicals as anti-cancer agents targeting cyclin dependent kinase-2, human topoisomerase IIa and vascular endothelial growth factor receptor-2

Discovery and resupply of pharmacologically active plant-derived natural products: A review

Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies

Cancer is a preventable disease that requires major lifestyle changes

Critical review: Vegetables and fruit in the prevention of chronic diseases

Plant-derived compounds in clinical trials

Biodiversity as a source of anticancer drugs

Directing biosynthesis

Lead-and drug-like compounds: The rule-of-five revolution. Drug discovery today

Sanjeevini: A freely accessible web-server for target directed lead molecule discovery

S7

SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules

Role of P-glycoprotein in pharmacokinetics: Clinical implications

P-glycoprotein Inhibition for optimal drug delivery

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences

Physicochemical characterisation, molecular docking, and drug-likeness evaluation of hypotensive peptides encrypted in flaxseed proteome. Current Research in Food Science

Molecular docking, PASS analysis, bioactivity score prediction, synthesis, characterization and biological activity evaluation of a functionalized 2-butanone thiosemicarbazone ligand and its complexes